[
  {
    "uuid": "1606861c306a7becc2c4b0b3531b172aa5557bb7",
    "url": "https://www.163.com/dy/article/K3GGHDMF0514D3UH.html",
    "ord_in_thread": 0,
    "author": "网易",
    "published": "2025-07-02T15:30:00Z",
    "title": "日航生死12分钟：万米高空速降7000米！孕妇呼吸急促，乘客含泪写遗书……|飞机|备降|航班|韩国客机_网易订阅",
    "text": "封面新闻记者 林梦晴\n6月30日，一架SPRING JAPAN（机票由国内的春秋航空代理）旗下IJ004航班从上海飞往东京途中突发增压系统异常，客机在万米高空紧急下降约7000米，备降关西机场。机上191名乘客和机组成员经历了生死12分钟——有乘客写下遗书，留下银行密码；怀胎28周的孕妇呼吸急促，紧张得说不清话；机舱后部传来隐隐的哭声。\n据日本国土交通省大阪航空局确认，机上191名乘客及机组人员均未受伤。具体事故原因正在调查。\n封面新闻\n，赞 36\n然而，备降后的漫长等待和日航后续处理方式再次引发乘客不满，赔偿承诺至今未兑现，多名乘客出现耳痛等身体不适症状。7月1日，封面新闻记者远程连线多名机上乘客还原事发经过。\n高空生死12分钟：“哥哥姐姐，我没氧气了”\n6月30日17时49分，一架SPRING JAPAN（机票由国内的春秋航空代理）旗下IJ004航班从上海浦东国际机场起飞，原定于21时47分抵达日本东京成田国际机场。但在飞行一个多小时后，客机出现异常。\n机上乘客武女士回忆，那时她刚接到“欢迎进入日本”的短信提醒，随即客机突然晃动了几秒。几乎在同一时间，机长进行了简短的广播，顶部的氧气面罩弹出。据懂日文的乘客翻译，机长怀疑客舱增压系统出现问题。\n武女士看到，正在过道服务的空乘人员愣了一下，随即跑回自己的位置，神色惊慌。“快点戴好氧气罩，系好安全带！”空姐大声急促地重复了多次指令。\n多位乘客向记者提及，最开始并不知道事情的严重性，动作也很迟钝，“我以为是航空演练，直到听到空姐声音颤抖、略带哭腔，才开始紧张。”由于很多乘客并无戴氧气面罩的经历，扯了很多次才扯断安全绳戴上。\n机上乘客正在吸氧/图源受访对象\n整个吸氧过程持续约12分钟。飞行APP显示，在此期间，飞机从1.1万米的高空快速下降至3200米左右。武女士形容前半段有失重感，“像在坐跳楼机”。她身旁坐着怀孕28周的孕妇，紧张得说不清话，呼吸非常急促。机舱后部还传来隐隐的哭声，武女士形容“听起来很绝望哀伤”。\n她的儿子也向封面新闻记者描述，由于过度紧张，呼吸急促，他的氧气消耗得很快，七八分钟后就用完了第一瓶。他随即和旁边的哥哥姐姐求助，“我没氧气了”。好在一旁空座位的氧气瓶还能继续使用，他一把扯过戴上。\n后半段的迫降，机舱异常安静，只剩吸氧声。在极度恐惧下，武女士想借用国际漫游包给丈夫发微信，却发现无法联网，只能在手机备忘录写下遗书。“万一我们走了，你要帮我照顾好我妈。你也要好好的。”她敲下5行，留下所有的保险、银行卡密码。\n“写完了都想哭，死都不知道怎么死的。”吴女士至今回想起来，仍心有余悸。\n乘客张先生也想过写遗书。降落期间，舱内灯光逐渐昏暗，温度开始升高，但飞机还算平稳。张先生感到明显的耳胀，此外无异样体感。低头看表，心率跳到103，略高。他本想为女友和母亲留下文字，但看着仍在运作的发动机又觉得问题不大，就此做罢。\n15分钟后，空乘人员宣布危险解除，可以摘下氧气面罩。劫后余生，很多乘客鼓起了掌。“吉人自有天相”，下机后武女士收到丈夫发来的信息。\n据日本国土交通省大阪航空局确认，机上191名乘客及机组人员均未受伤或出现身体不适。具体事故原因正在调查中。\n专家解读：为何客机突降7000米？\n据日航7月1日发布的情况说明，涉事航班在飞行过程中，飞行员发现增压系统出现异常指示，为确保旅客与机组成员的安全，将飞机降低到安全飞行高度，并于20时48分在关西国际机场备降。\n增压系统异常会导致怎样的后果，为何飞机需要迫降约7000米？\n资深机长陈建国介绍，民航客机通常在高度9000至12000米巡航，此时外界空气稀薄、温度极低，飞机必须通过增压系统提高座舱内空气密度和温度，以保障乘客正常呼吸和舒适度。增压后，舱压相当于地面2400米以内的气压，维持约24℃的舱温。\n如果增压系统出现故障，机舱氧气含量会迅速下降，乘客可能在数分钟内因缺氧失去意识。因此一旦发生座舱失压，氧气面罩会自动脱落供氧，机组必须在氧气瓶有效供氧的15—20分钟内，将飞机紧急下降到可呼吸的安全高度（通常为3000米左右）。\n陈建国表示，本次事件中，机组在约10分钟内完成紧急下降，属于标准的应急操作程序。从雷达图看，飞机最大下降率达到了1400米每分钟，在应急下降过程中属于正常下降率。\n日航声明遭到乘客质疑\n风波仍在发酵。\n据武女士描述，飞机备降后，乘客们开始了漫长的等待。先是因机组成员检查客机，所有人在机上停留一个多小时。在确认飞机难以继续行程后，乘客们下机，等待行李超过2小时，期间只能站着。武女士强调，其中还包括一名孕妇，无绿色通道或轮椅协助。\n与孕妇的聊天记录/图源受访对象\n“全程无工作人员安抚或道歉，也不提供水食。”张先生抱怨道。直至凌晨12点多，乘客们才坐上前往酒店的大巴，办完入住已是凌晨3点。\n种种不满在日航表态后集中爆发。7月1日，日本航空JAL发布情况说明称，“目前为止，尚未收到乘客或机组人员出现身体不适的报告，关于增压系统出现异常的具体原因正在进一步调查中。”\n然而，多名乘客提出异议。对于公告中“尚未收到乘客出现身体不适的报告”，武女士表示，事发后并无人对乘客进行身体检查，自己和许多乘客的耳朵仍剧烈疼痛，计划归国后自费进行听力检测。\n关于经济赔偿，机组人员曾承诺给予前往最终目的地的交通补助费用，额度为15000日元。但据武女士反映，航司并未说明赔偿渠道，也无人收到赔偿。且乘客们还面临其他经济损失，如无法退费的民宿，作废的景点门票。与武女士同行的两个伙伴受到惊吓后，选择终止行程，直接回国。\n乘客们尝试通过多种渠道了解后续处理方案，包括联系航空公司客服、大阪领事馆等，但均表示沟通效果有限。\n7月2日，封面新闻记者拨打春秋航空日本的客服电话，对方表示可向航司发送邮件说明情况。截至发稿前，暂未收到邮件回复。",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "chinese",
    "sentiment": "negative",
    "categories": [
      "Disaster and Accident",
      "Health",
      "Human Interest"
    ],
    "topics": [
      "Disaster and Accident->transportation accident and incident",
      "Disaster and Accident->emergency response",
      "Health->health care approach",
      "Health->emergency care",
      "Health->medical condition",
      "Human Interest->human mishap"
    ],
    "ai_allow": true,
    "has_canonical": false,
    "breaking": null,
    "webz_reporter": false,
    "external_links": [],
    "entities": {
      "persons": [],
      "locations": [],
      "organizations": []
    },
    "syndication": {
      "syndicated": null,
      "syndicate_id": null,
      "first_syndicated": false
    },
    "trust": {
      "categories": [],
      "top_news": [
        "top_news_vn",
        "top_news_th",
        "top_news_nz",
        "top_news_rs",
        "top_news_sg",
        "top_news_tw",
        "top_news_hk",
        "top_news_my",
        "top_news"
      ],
      "bias": null
    },
    "rating": null,
    "crawled": "2025-07-03T08:30:02.032+03:00",
    "updated": "2025-07-04T06:05:14.000+00:00"
  },
  {
    "uuid": "61ae82eab06621d46c573e82f6ee0898ad17f7bd",
    "url": "https://gestion.pe/peru/politica/sutep-anuncia-inicio-de-huelga-de-hambre-en-nueva-movilizacion-al-mef-noticia",
    "ord_in_thread": 0,
    "parent_url": null,
    "author": "Redacción Gestión",
    "published": "2024-08-08T20:22:00Z",
    "title": "Sutep anuncia inicio de huelga de hambre en nueva movilización al MEF | PERU | GESTIÓN",
    "text": "En una nueva movilización los maestros y auxiliares del [Sutep](https://gestion.pe/noticias/sutep/) volverán a exigir al [ Ministerio de Economía](https://gestion.pe/noticias/mef/) que eleve el presupuesto del sector Educación a no menos del 6 % del PBI para el próximo año, pues solo el cumplimiento de la Constitución permitirá contar con mejor infraestructura, cuidado de la salud y alimentación de los estudiantes, además de pensiones y remuneraciones dignas para el magisterio. Previo a la movilización del viernes 9 de agosto, los integrantes del SUTEP participarán en la III Asamblea Nacional de Delegados para decidir la fecha en que los dirigentes del gremio iniciarán una huelga de hambre, “medida extrema pero necesaria” , según indicó el Sutep, para exigir al gobierno que cumpla con acuerdos suscritos entre el gremio y el Minedu. La decisión será anunciada durante la movilización. El Sutep recordó también al gobierno que de no cumplir los acuerdos y justas demandas las bases desarrollarán posteriormente una [ huelga nacional indefinida](https://gestion.pe/noticias/huelga-nacional-indefinida/). LEA TAMBIÉN: [Sutep rechaza populismo del Congreso al insistir con nombramiento automático para docentes] ¿Cuáles son las demandas del Sutep?: - Garantizar mayor presupuesto para Educación. (Constitución ordena 6 % del PBI) - Plan de reducción de la brecha en la infraestructura educativa. - Pago de 400 soles por escolaridad a más de 73 mil docentes recientemente nombrados. - Respeto a la ley que dispone el aumento para los auxiliares de educación equivalente al 85 % de la RIM de la primera escala salarial docente y que el gobierno se niega a cumplir. - Al Congreso demandamos la aprobación del Proyecto de Ley para el pago del bono de 380 soles a maestros y auxiliares nombrados y contratados, acuerdo del Convenio Colectivo SUTEP-Minedu. - Incremento de bonificaciones para nuestros docentes “soldados de la patria” que trabajan en zona rural, frontera y VRAEM. LEA TAMBIÉN: [Sutep propone evitar que profesores condenados por terrorismo enseñen en los cole] - Incremento de 500 soles a la remuneración docente en el 2025. - Asegurar 2do tramo del bono excepcional de 487 soles en el 2025 a docentes y auxiliares. - Pensiones dignas para cesantes y jubilados Comienza a destacar en el mundo empresarial recibiendo las noticias más exclusivas del día en tu bandeja [Aquí]. Si aún no tienes una cuenta, [Regístrate gratis]y sé parte de nuestra comunidad.",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "spanish",
    "sentiment": "negative",
    "categories": [
      "Labor",
      "Social Issue"
    ],
    "ai_allow": true,
    "webz_reporter": false,
    "external_links": [],
    "external_images": [],
    "entities": {
      "persons": [],
      "organizations": [],
      "locations": []
    },
    "rating": null,
    "crawled": "2024-08-09T00:41:42.477+03:00",
    "updated": "2024-08-09T00:41:42.477+03:00"
  },
  {
    "uuid": "304aee262000458229ed1aad349aec73a79024a4",
    "url": "https://uk.advfn.com/stock-market/london/puretech-health-PRTC/share-news/PureTech-Health-PLC-FDA-Grants-PRTCs-LYT-200-Fast/93636657",
    "ord_in_thread": 0,
    "parent_url": null,
    "author": "uk.advfn.com",
    "published": "2024-04-11T10:00:00Z",
    "title": "PureTech Health PLC FDA Grants PRTC's LYT-200 Fast Track Designation - ADVFN",
    "text": "RNS Number : 1294K PureTech Health PLC 11 April 2024\n11 April 2024\nPureTech Health plc\nPureTech R eceives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers\nLYT-200 is being evaluated in locally advanced/metastatic solid tumors, including head and neck cancer s, as well as in hematological malignancies, such as acute myeloid leukemia and high-risk myelodysplastic syndrome\nPhase 1b and Phase 1/2 clinical trials of LYT-200 ongoing\nPureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (\"PureTech\" or the \"Company\"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that the U . S . Food and Drug Administration (\"FDA\") has granted Fast Track designation for LYT-200 in combination with anti-PD1 therapy for the treatment of recurrent/metastatic head and neck squamous cell carcinomas (\"head and neck cancers\").\n\"In the U.S., there are approximately 66,000 people diagnosed with head and neck cancers each year, and the prognosis for metastatic disease is unfavorable, with a median survival rate of about ten months,\" said Eric Sherman, M.D., Memorial Sloan Kettering Cancer Center and an investigator in PureTech's Phase 1/2 clinical trial. \"There is an important need to explore promising new mechanisms and targets such as galectin-9 to bring therapeutic innovation to this patient population.\"\nLYT-200 is an antibody against galectin-9, a potent cancer driver, and is the most advanced clinical program against this target. It is being evaluated in two ongoing clinical trials:\n1. a Phase 1/2 adaptive design trial in advanced/metastatic solid tumors, including head and neck cancers. In this trial, LYT-200 is being evaluated as a monotherapy and in combination with tislelizumab, an anti-PD-1 antibody developed by BeiGene. LYT-200 has demonstrated a favorable safety profile in all cohorts, including the monotherapy and combination arms with BeiGene's tislelizumab, and shown disease control and suggestions of initial anti-tumor activity.\n2. a Phase 1b clinical trial evaluating LYT-200 as a monotherapy and in combination with venetoclax and hypomethylating agents in hematological malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome. LYT-200 has demonstrated a favorable safety and tolerability profile as well as early signals of potential clinical activity.\n\"By granting Fast Track designation to LYT-200 for head and neck cancers, the FDA continues to highlight areas of critical need within oncology as well as the potential for LYT-200 ,\" said Aleksandra Filipovic, M.D., Ph.D., Head of Oncology at PureTech. \"As galectin-9's role in suppressing immune-mediated activity has been well-validated, it represents an important area of clinical research, especially in aggressive cancers with increased mortality.\"\nFast Track designation is a process designed to streamline the development and accelerate the assessment of drugs that target serious conditions with unmet medical need. The FDA has also granted o rphan d rug d esignation to LYT-200 for the treatment of AML .\nAbout LYT-200\nLYT-200 is a fully human IgG4 monoclonal antibody targeting galectin-9 for the potential treatment of locally advanced/metastatic solid tumors that have poor survival rates, including head and neck cancers. It is also in development for the treatment of hematological malignancies, such as acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Galectin-9 is a potent oncogenic driver and immunosuppressor , and in AML it has been described to work via engagement with cytotoxic CD8 T cells and natural killer cells.\nA wide variety of preclinical data underscores the importance of galectin-9 as a target and suggests a potential opportunity for biomarker development. These data demonstrate high expression of galectin-9 across various blood cancers and solid tumor types and show that galectin-9 levels correlate with poor survival in several cancers.\nLYT-200 has demonstrated direct cytotoxic, anti-leukemic effects through multiple mechanisms, as well as synergy with standard of care chemotherapy and venetoclax in preclinical models. Consistent with its hub-and-spoke model, PureTech intends to advance LYT-200 via its Founded Entity Gallop Oncology.\nAbout PureTech Health\nPureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 28 therapeutics and therapeutic candidates, including two that have received both U.S. FDA clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.\nFor more information, visit www.puretechhealth.com or connect with us on X (formerly Twitter) @puretechh.\nCautionary Note Regarding Forward-Looking Statements\nThis press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those related to the LYT-200 development program and the timing for results from ongoing clinical trials of LYT-200 , and our future prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption \"Risk Factors\" in our Annual Report on Form 20-F for the year ended December 31, 2022 filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.\nContact:\nPureTech\nPublic Relations\npublicrelations@puretechhealth.com\nInvestor Relations\nIR@puretechhealth.com\nUK/EU Media\nBen Atwell, Rob Winder\n+44 (0) 20 3727 1000\npuretech@fticonsulting.com\nUS Media\nNichole Bobbyn\n+1 774 278 8273\nnichole@tenbridgecommunications.com\nThis information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com .\nRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy . END NRAKZGMDGMFGDZG",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "english",
    "sentiment": "positive",
    "categories": [
      "Science and Technology",
      "Health"
    ],
    "external_links": [
      "http://www.rns.com/",
      "https://puretechhealth.com/",
      "https://news.puretechhealth.com/news-releases/news-release-details/puretech-receives-orphan-drug-designation-lyt-200-acute-myeloid",
      "https://www.lseg.com/privacy-and-cookie-policy",
      "http://rns.com/",
      "https://www.puretechhealth.com/",
      "https://lseg.com/privacy-and-cookie-policy",
      "http://www.rns.com",
      "https://www.news.puretechhealth.com/news-releases/news-release-details/puretech-receives-orphan-drug-designation-lyt-200-acute-myeloid",
      "https://puretechhealth.com"
    ],
    "external_images": [],
    "entities": {
      "persons": [],
      "organizations": [
        {
          "name": "puretech health plc",
          "sentiment": "negative"
        },
        {
          "name": "prtc",
          "sentiment": "negative"
        },
        {
          "name": "puretech health",
          "sentiment": "negative"
        },
        {
          "name": "puretech health plc fda",
          "sentiment": "negative"
        },
        {
          "name": "fda",
          "sentiment": "none"
        }
      ],
      "locations": [
        {
          "name": "u.s.",
          "sentiment": "none"
        }
      ]
    },
    "rating": null,
    "crawled": "2024-04-12T00:29:04.092+03:00",
    "updated": "2024-04-12T00:29:04.092+03:00"
  },
  {
    "uuid": "089750b135deb78974d46a65ebc2a297c600bf78",
    "url": "https://www.prokerala.com/news/articles/a1492052.html",
    "ord_in_thread": 0,
    "parent_url": null,
    "author": "@prokerala",
    "published": "2023-12-29T06:03:00Z",
    "title": "SGPC chief says enacting the Sahibzadas against Sikh traditions, demands explanation",
    "text": "Amritsar, Dec 29 : The Shiromani Gurdwara Parbandhak Committee (SGPC) on Friday slammed the physical depiction of the Sahibzadas, the sons of last Sikh Guru, Guru Gobind Singh, in plays by children in schools under the Veer Bal Diwas events announced by the Central government, terming it against Sikh principles and traditions. It has sought an explanation from the Central Board of Secondary Education (CBSE) along with the Union Ministries of Education, Culture, and Minority Affairs. SGPC President Harjinder Singh Dhami said any such anti-Sikh act cannot be accepted. He said any act against Sikh principles, customs, traditions, and values hurts the Sikh mentality and big objections are coming from the Sikh sangat about the enacting the Sahibzadas under the instructions of the Centre government regarding Veer Bal Diwas in educational institutions in various states. He said taking cognisance of these acts against the Sikh principles, the SGPC has asked Union ministries and the CBSE to present their stand. Dhami said regarding Veer Bal Diwas, according to the order of Akal Takht Sahib, the Union government had already been approached to change the name of this day, but it has not taken it seriously till date. He said the concern of the SGPC and the Sikh sangat in this regard has come true as efforts are being made to make children play the roles of Sahibzadas by going against the Sikh traditions. He said the responsibility of this anti-Sikh phenomenon lies directly on the Union government and the respective state governments. Such actions can never be accepted by the Sikh world and action will also be taken against the educational institutions by identifying them, that have got the characters of Sahibzadas played in physical form, Dhami said.",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "english",
    "sentiment": "negative",
    "categories": [
      "Social Issue",
      "Religion and Belief"
    ],
    "external_links": [],
    "external_images": [],
    "entities": {
      "persons": [
        {
          "name": "sahibzadas",
          "sentiment": "negative"
        },
        {
          "name": "akal takht sahib",
          "sentiment": "none"
        },
        {
          "name": "dhami",
          "sentiment": "none"
        },
        {
          "name": "guru gobind singh",
          "sentiment": "none"
        },
        {
          "name": "harjinder singh dhami",
          "sentiment": "none"
        }
      ],
      "organizations": [
        {
          "name": "sgpc",
          "sentiment": "negative"
        },
        {
          "name": "shiromani gurdwara parbandhak committee",
          "sentiment": "negative"
        },
        {
          "name": "minority affairs",
          "sentiment": "none"
        },
        {
          "name": "union ministries of education",
          "sentiment": "none"
        },
        {
          "name": "central board of secondary education",
          "sentiment": "none"
        },
        {
          "name": "union",
          "sentiment": "none"
        },
        {
          "name": "cbse",
          "sentiment": "none"
        }
      ],
      "locations": [
        {
          "name": "amritsar",
          "sentiment": "none"
        }
      ]
    },
    "rating": null,
    "crawled": "2023-12-29T13:21:56.597+02:00",
    "updated": "2023-12-29T13:21:56.597+02:00"
  },
  {
    "uuid": "d4a26f35f0d5d8cc34074532af8c30ac28233e60",
    "url": "https://whatnow.com/miami/real-estate/new-192-unit-housing-project-proposed-for-rezoning-in-south-miami-dade/",
    "ord_in_thread": 0,
    "author": "Riya Singh",
    "published": "2025-07-15T18:41:00Z",
    "title": "New 192-Unit Housing Project Proposed for Rezoning in South Miami-Dade",
    "text": "A new housing project is underway in the Goulds neighborhood of South Miami-Dade County. As plans for the project continue, the developers are seeking to rezone the property. The developers have proposed rezoning the site to allow for a 192-unit residential project.\nHighlights\n- The housing project in Miami plans to rezone to a high-density apartment house district.\n- The new plan offers affordable apartments for workforce housing.\n- The project offers a variety of units and comfortable amenities.\nRezoning for 192-unit Summerbreeze Apartments\nNew housing projects remain active across Miami-Dade County, continuing to shape local neighborhoods. The latest information is from the Summerbreeze Apartments project in the Goulds neighborhood. The 4.6-acre site, acquired in 2015 and 2016, is slated for a new residential development.\nThe site was initially zoned for lower-density residential use, but developers have since updated their plans. There has been a change by the developers, 232 Holdings LLC and 12499 Holdings LLC, led by Charles S. Sacher. They have submitted a pre-application for the rezoning of the project.\nAccording to a report by the South Florida Business Journal, the minimum apartment house district plans in Miami-Dade’s Gould neighborhood are to be rezoned. It will now be a high-density apartment house district. The new designation would allow the developers to increase the number of housing units on the property.\nThe plans will now be for a 192-unit four-story project. 40% of the units will be designated as workforce housing for residents earning up to 120% of the area’s median income. According to HUD, the median household income in Miami-Dade is $79,400.\nThe developers are also seeking a density bonus to build more units than typically allowed under the high-density designation. It permits them to build more units than approved by the high-density zoning.\nProject Features\nThe Summerbreeze Apartments will spread across 192,804 square feet in four stories. The four-story development will include 192 units and 279 parking spaces. The apartments include: 16 studio units, 92 one-bedroom units, 80 two-bedroom units, and four three-bedroom units. These will range from 546 square feet to 1,120 square feet each.\nPlanned amenities at Summerbreeze Apartments include a pool, fitness center, and clubroom. The project location is on the north side of the C-102 Canal. It is near U.S. 1 and Southwest 232nd Street. While the site is located outside major employment hubs, residents will have access to the South Dade TransitWay’s EV bus rapid transit system.\nThe developers have filed the pre-applications for the rezoning. Once feedback is received, they will submit the official documents. This is only the beginning and would need approval from the County Commission later.",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "english",
    "sentiment": "positive",
    "categories": [
      "Economy, Business and Finance",
      "Lifestyle and Leisure",
      "Human Interest"
    ],
    "topics": [
      "Economy, Business and Finance->construction and property",
      "Economy, Business and Finance->business strategy and marketing",
      "Lifestyle and Leisure->lifestyle",
      "Lifestyle and Leisure->house and home",
      "Lifestyle and Leisure->trend"
    ],
    "ai_allow": true,
    "has_canonical": false,
    "breaking": null,
    "webz_reporter": false,
    "external_links": [
      "https://www.bizjournals.com/southflorida/news/2025/07/14/coinco-plans-summerbreeze-apartments-goulds-miami.html",
      "https://bizjournals.com/southflorida/news/2025/07/14/coinco-plans-summerbreeze-apartments-goulds-miami.html"
    ],
    "external_images": [],
    "internal_images": [],
    "entities": {
      "persons": [
        {
          "name": "Charles S. Sacher",
          "sentiment": "none"
        }
      ],
      "locations": [
        {
          "name": "South Miami-Dade County",
          "sentiment": "none"
        }
      ],
      "organizations": [
        {
          "name": "Holdings LLC",
          "sentiment": "none",
          "tickers": []
        }
      ]
    },
    "syndication": {
      "syndicated": false,
      "syndicate_id": null,
      "first_syndicated": false
    },
    "trust": {
      "categories": [],
      "top_news": [],
      "bias": null,
      "source": {
        "type": null,
        "city": null,
        "state": null,
        "country": null,
        "domain_type": null,
        "agency": null,
        "organization_name": null
      }
    },
    "rating": null,
    "crawled": "2025-07-24T07:47:53.775+03:00",
    "updated": "2025-07-24T07:51:31.000+03:00"
  }
]